Supernus Pharmaceuticals SUPN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $186.32M+43.4% | $129.9M-15.0% | $152.82M+5.6% | $144.71M+24.9% | $115.85M+67.1% | ||
| $182.18M-3.0% | $187.8M+9.7% | $171.25M+21.6% | $140.83M-3.3% | $145.64M+2.5% | ||
| $23.71M-21.2% | $30.1M+8.6% | $27.7M-37.1% | $44.02M-10.9% | $49.42M— | ||
| $731.58M+13.6% | $644.18M+8.5% | $593.89M-19.6% | $738.87M+7.5% | $687.58M+0.2% | ||
| $10.04M-4.6% | $10.53M-0.9% | $10.63M-4.0% | $11.07M-2.4% | $11.34M-1.8% | ||
| $120.67M-3.4% | $124.88M+4.9% | $119.08M+1.8% | $117.02M0.0% | $117.02M0.0% | ||
| $549.71M-3.5% | $569.46M-8.7% | $623.48M+29.5% | $481.31M-4.1% | $502.13M-3.8% | ||
| $1.5B+3.3% | $1.45B+2.3% | $1.42B+2.7% | $1.38B+2.6% | $1.35B-1.5% | ||
| $373.93M+10.6% | $338.17M+2.3% | $330.63M+15.5% | $286.36M+1.6% | $281.77M-3.6% | ||
| $206K-99.3% | $31.26M-91.6% | $370.09M+16.2% | $318.51M+0.6% | $316.59M-4.7% | ||
| 130M0.0% | 130M0.0% | 130M0.0% | 130M0.0% | 130M+232,043% | ||
| $515.58M-0.4% | $517.88M-0.8% | $521.98M-8.0% | $567.1M+4.1% | $544.6M-2.1% | ||
| $1.08B+1.4% | $1.06B+1.1% | $1.05B-1.3% | $1.06B+3.2% | $1.03B-0.5% | ||
| $1.5B+3.3% | $1.45B+2.3% | $1.42B+2.7% | $1.38B+2.6% | $1.35B-1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Supernus Pharmaceuticals's total assets?
- Supernus Pharmaceuticals (SUPN) holds $1.5B in total assets, up 11.4% year over year.
- How much debt does Supernus Pharmaceuticals have?
- Supernus Pharmaceuticals carries $40.9M in total debt against $1.1B of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does Supernus Pharmaceuticals have?
- Supernus Pharmaceuticals holds $186.3M in cash and equivalents.
- Can Supernus Pharmaceuticals cover its short-term obligations?
- Its current ratio is 1.96 — current assets exceed current liabilities.
- Where does Supernus Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
